INNOVATIVE APPROACHES IN CARDIOVASCULAR DISEASE

nytt-bilde.jpg

Investor relations

/share/mime/pdf.gifEGF 15 02 2012 protocol
(120215-protokoll-sign.pdf, 361kB)

Investor information

/share/mime/pdf.gifProspectus
(110455_serodus_prospekt_finalweb.pdf, 5MB)
/share/mime/pdf.gifProspectus supplement
(serodus_supplemental-prospectus.pdf, 255kB)
/share/mime/pdf.gif2011 Q1 report
(serodus-q1-2011-interim-report_final.pdf, 322kB)
/share/mime/pdf.gif2010 Q4 report
(serodus-q4-2010-report.pdf, 305kB)

Links

Corporate Governance

/share/mime/pdf.gifCode of ethics and conduct
(serodus-code-of-ethics-and-conduct-serodus.pdf, 72kB)
/share/mime/pdf.gifGuidelines for insiders (in Norwegian)
(serodus-asa-retningslinjer-for-kurssensitiv-informasjon-og-innsidereglement.pdf, 204kB)
/share/mime/pdf.gifGuidelines for non-auditing work
(serodus-guidelines-non-auditing-work.pdf, 50kB)
/share/mime/pdf.gifBoard instructions (in Norwegian)
(serodus-styreinstruks.pdf, 65kB)
/share/mime/pdf.gifCEO Instructions (in Norwegian)
(ceo-instructions.pdf, 64kB)
/share/mime/pdf.gifGuidelines related to take-over bids
(serodus-guidelines-relating-to-take-over-bids.pdf, 44kB)
/share/mime/pdf.gifGuidelines for related party transactions
(serodus-guidelines-related-party-transactions.pdf, 42kB)
latestnews.jpg

Serodus ASA
Gaustadalléen 21
N-0349 Oslo, Norway

Tel: +47 22 95 81 91
Fax: +47 22 60 44 27


Send us a mail
post@serodus.com

Utviklet av Renommé Communication